

Newcastle Disease (ND) is caused by virulent strains of avian paramyxovirus type 1 (APMV-1) of the genus Avulavirus which belongs to the family Paramyxoviridae. The ND virus (NDV) has shown to be able to infect over 200 species of birds, but the severity of the disease produced varies with both the host and the strain of the virus. Even APMV-1 strains of low virulence may induce severe respiratory diseases when exacerbated by the presence of other organisms or by adverse environmental conditions. Since its recognition in 1926, ND is regarded as being endemic in many countries (www.oie.int).

IB comes in many colours

Since the first reports of Infectious Bronchitis, IBV has continued to change its appearance. Outbreaks can be explosive, with the virus spreading rapidly to involve the entire flock within only a few days. The incubation period is typically brief: 18 to 48 hours. In chicks from 1 to 4 weeks of age, virulent virus strains produce severe respiratory disease, with gasping, coughing, tracheal rales, sneezing, nasal exudate, wet eyes, respiratory distress. Occasionally, also swollen sinuses appear, just like kidney problems and negative effects on egg production. A higher mortality is also many times reported, mainly in young birds. In birds in lay, infections with IBV may cause a significant drop in egg production and/or in the quality of the eggs.

EDS

Since its initial description, EDS virus has become a major cause of lost egg production throughout the world. The disease is characterized by the production of thin-shelled or shell-less eggs by otherwise healthy birds. Once established in a breeding organization, the condition more often is seen as a failure to achieve production targets, and eggshell changes are less apparent. Since its initial recognition, it has become apparent that sporadic outbreaks of EDS occur as a result of fowl becoming infected through direct or indirect contact with infected wild or domestic waterfowl.

SOURCE: Diseases of Poultry, Y.M Saif - 11 th Edition

Chapter: Egg Drop Syndrome - John Brian McFerran and Brian McConnell Adair

Source: www.oie.int

VAXXON® ND-IB-EDS - A single shot to expand the protection during the laying period



Target Species

Chicken (layers and breeders).

Indications



VAXXON® ND-IB-EDS provides active immunization of breeders and layers against Newcastle Disease, Avian Infectious Bronchitis and Egg Drop Syndrome (EDS).

Dosage and method of administration

Each vial contains 500 ds (250 ml) or 1,000 ds (500 ml).

18 - 20 weeks

Method of administration

Vaccination can be done subcutaneously (at the back of the neck) or intramuscularly (in the pectoral muscles) at 18-20 weeks, before the laying period. A first vaccination with live vaccines against Newcastle Disease and Infectious Bronchitis is recommended.



Composition

Each dose of 0.5 ml of vaccine contains sufficient:

- Inactivated Newcastle Disease virus.
- Inactivated Infectious Bronchitis virus strain Massachusetts.
- Inactivated EDS '76 virus.

In oil emulsion.



Shelf life

The product in the original packaging can be used until 24 months from the manufacturing date.

Storage conditions

The product must be stored at 2°C to 8°C. Do not freeze. Protect from light.

DISCLAIMER

This brochure may contain information or may show or refer to products and/or services which are only available in certain countries. A reference to any product/service in this brochure does not imply that such product or such product with the same specifications et cetera, is or will be available at your location. Any product shown or referred to in this brochure may be subject to different regulatory requirements depending on the country of use. Please contact your local Vaxxinova representative for more information.


Vaxxinova International BV does not give any warranty or other assurance as to the content of this brochure, its accuracy, completeness, timelessness or fitness for any particular purpose. To the full extent permissible by law, Vaxxinova International BV disclaims all responsibility for any damages or losses (including without limitation, financial loss, damages for loss in business projects,

loss of profits or other consequential losses) arising in contract, tort or otherwise from the use of inability to use any material of Vaxxinova, or from any action or decision taken as a result of using Vaxxinova's materials. Vaxxinova disclaims all responsibility and liability (including for negligence) in relation to information mentioned in Vaxxinova's materials. This document or its content is not to be copied or further distributed without the consent of Vaxxinova International BV.

VAXXINOVA, VAXXON and GOVAXX are registered trademarks of Vaxxinova International B.V. (the Netherlands).

Version 5 2024.03 120953







Vaxxinova International BV

Transistorweg 5 6534 AT Nijmegen The Netherlands +31 24 20 48 600 www.vaxxinova.com

